Irina Barash

机构：Merck & Co., Inc., Rahway, NJ, USA (United States) · ORCID：0000-0002-0358-6591

发表论文 32 篇 · 总被引 771 次 · h-index 15

代表论文

• Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial (2025 · The Lancet · 被引 82)
• Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease (2017 · Journal of the American Society of Nephrology · 被引 75)
• Deployed Deep Learning Kidney Segmentation for Polycystic Kidney Disease MRI (2022 · Radiology Artificial Intelligence · 被引 57)
• Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials (2025 · The Lancet · 被引 45)
• Detection of PKD1 and PKD2 Somatic Variants in Autosomal Dominant Polycystic Kidney Cyst Epithelial Cells by Whole-Genome Sequencing (2021 · Journal of the American Society of Nephrology · 被引 38)
• Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease (2020 · Journal of Magnetic Resonance Imaging · 被引 24)